Dr Reddy's Labs to set up biotech production facilitiesIllustrative image – not actual.

Dr. Reddy’s Laboratories Ltd (DRL) is setting up biotech production facilities conforming to US FDA specifications. The project includes setting up of three class-10,000 bulk recombinant protein production suites and a new formulations facility. DRL has already invested Rs.10 crore in this project.

 

DRL’s biotech business focuses on molecular biology, cell culture, fermentation, downstream, processing and hybridoma technology. The company has already launched Grastim, which serves as an import-substitute cancer therapy drug.

← All latest storiesBack to top →